Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.6% during the fourth quarter, HoldingsChannel reports. The firm owned 58,159 shares of the biotechnology company’s stock after buying an additional 354 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Exelixis were worth $1,937,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 290 shares in the last quarter. Covestor Ltd lifted its stake in shares of Exelixis by 5.7% in the third quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 341 shares in the last quarter. Principal Securities Inc. lifted its stake in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in shares of Exelixis by 37.3% in the fourth quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 425 shares in the last quarter. Finally, Fifth Third Bancorp lifted its stake in shares of Exelixis by 16.1% in the fourth quarter. Fifth Third Bancorp now owns 3,231 shares of the biotechnology company’s stock worth $108,000 after acquiring an additional 449 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Up 2.8 %

Shares of Exelixis stock opened at $38.69 on Friday. The business’s 50 day simple moving average is $34.53 and its 200-day simple moving average is $31.62. The stock has a market capitalization of $10.83 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $38.72.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Sell-side analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on EXEL shares. Brookline Capital Management started coverage on Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating on the stock. Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. JMP Securities restated a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Exelixis in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Exelixis presently has an average rating of “Moderate Buy” and a consensus target price of $37.24.

Insider Buying and Selling

In related news, CFO Christopher J. Senner sold 29,314 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the transaction, the chief financial officer now directly owns 779,607 shares of the company’s stock, valued at $28,174,996.98. This represents a 3.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the transaction, the director now directly owns 356,605 shares of the company’s stock, valued at $13,479,669. This trade represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 130,343 shares of company stock valued at $4,789,234 in the last three months. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.